FDA Announces Plans to Restrict Non-Approved GLP-1 Drugs in Compounded Medications
Today, the U.S. Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded…
Read the full articleYou might also wanna read
Navigating the Gray Area: The Unregulated Surge of Unique GLP-1 and GLP-1/GIP Products
Purpose: To identify unique compounded semaglutide and tirzepatide products that existed after the shortage grace period ended and to assess
Compounded peptides placed on restrictive list by FDA, lawsuit filed
The FDA is evaluating the future of compounded peptides, which are popular short-chain amino acids that signal cells to perform specific bio
Experts warn easy access to GLP-1 drugs may increase eating disorder risks
With GLP-1s readily available, some experts fear misuse is increasing and may be fueling eating disorders. Physicians describe what they are
mdsc.pe·27d ago1 in 9 Americans Now on GLP-1s
A recent Gallup poll shows that the use of GLP-1 drugs in the US has surged to a record high, with 11% of US adults currently using these me
Here's how many Americans say they are now taking GLP-1 drugs
As GLP-1 drugs become more widely available, they are reshaping how Americans approach weight management and chronic disease prevention. The
Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.
Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.
Comments
Sign in to join the conversation.
No comments yet. Be the first.